The Role of the JAK-STAT Signaling Pathway in the Protective Effects of Hepatic Ischemia Post-conditioning Against...

Area of Science:

• Hepatology
• Immunology
• Molecular Biology

Background:

• Ischemia/reperfusion (IR) injury significantly impacts liver health.
• Hepatic ischemic post-conditioning (IPOC) offers protection against IR injury, but its underlying mechanisms are not fully understood.
• Investigating the molecular pathways involved in IPOC is crucial for developing targeted therapies.

Purpose of the Study:

• To elucidate the role of the interleukin-6 Janus kinase-signal transducers and activators of transcription (IL-6-JAK-STAT) pathway in the protective effects of hepatic IPOC.
• To determine if the IL-6-JAK-STAT pathway mediates the liver's response to IPOC following IR injury.
• To assess the impact of JAK-STAT inhibition on IPOC-mediated liver protection.

Main Methods:

• A rat model was used, with groups subjected to sham operation, IR, IR+IPOC, IR+tofacitinib (JAK-STAT inhibitor), and IR+tofacitinib+IPOC.
• Liver injury was evaluated through enzyme release (AST, ALT), histopathological examination, IL-6 serum levels, and apoptosis markers (Bax/Bcl-2 ratio).
• The effect of tofacitinib on IPOC-induced protection was assessed.

Main Results:

• Hepatic IPOC significantly reduced liver injury markers (histology, AST, ALT) and IL-6 levels compared to IR alone (P<0.001, P<0.05, P<0.05).
• IPOC also led to a downregulation of the Bax/Bcl-2 ratio, indicating reduced apoptosis (P<0.05).
• Tofacitinib treatment inhibited the protective effects of hepatic IPOC, suggesting a role for JAK-STAT signaling.

Conclusions:

• The findings suggest that the protective effect of hepatic IPOC against IR-induced liver injury is mediated by the activation of the IL-6-JAK-STAT pathway.
• Targeting the IL-6-JAK-STAT pathway could be a therapeutic strategy for managing hepatic IR injury.
• This study provides novel insights into the molecular mechanisms of liver protection by IPOC.